BioNTech SE (BNTX) Reports Q1 EPS of EUR14.24, Reiterates FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BioNTech Announces First Quarter Financial Results and Corporate Update
May 9, 2022 6:01 AM EDTFirst quarter revenues of 6.4Â billion1, net income of 3.7Â billion and fully diluted earnings per share of 14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of 13 billion to 17 billionFirst-in-class CAR-T program targeting CLDN-6 (BNT211) in solid tumors showed manageable safety profile and signs of clinical activity; preliminary Phase 1/2 data presented at AACR Annual Meeting 2022Continued pipeline expansion to 16 clinical stage oncology programs in 20 ongoing clinical trialsÂ
Conference call and webcast scheduled for May 9, 2022, at 8:00 am ET (2:00 pm CET)
... More